Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer’s disease portfolio at CTAD 2026
Basel, 10 November 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will present new data across its pharmaceuticals and diagnostics portfolios at the 19 th Clinical Trials on Alzheimer’s Disease (CTAD) Congress, taking place in Boston, MA, from 16–19 November 2026. Across 16 accepted abstracts, including two scientific symposia and two oral presentations, Roche will highlight its differentiated approach to neurodegeneration: uniting high-accuracy diagnostic testing with targeted investigational therapeutics to address the disease across its continuum.